NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. - Wikidata - wikimedia - TriplyDB

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

http://www.wikidata.org/entity/Q30528889

about

Potential Roles of Fungal Extracellular Vesicles during Infection How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?The Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine Antigens How Chemotherapy Increases the Risk of Systemic Candidiasis in Cancer Patients: Current Paradigm and Future Directions New insights on the development of fungal vaccines: from immunity to recent challenges Studies of Immune Responses in Candida vaginitis IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans Emerging drugs and vaccines for candidemia New insights into innate immune control of systemic candidiasis An Update on Clinical Burden, Diagnostic Tools, and Therapeutic Options of Staphylococcus aureus Immunity against fungi.Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Inhibition of Pseudomonas aeruginosa with a recombinant RNA-based viral vector expressing human β-defensin 4.Fungal vaccines and immunotherapeutics.Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.The hierarchical process of differentiation of long-lived antibody-secreting cells is dependent on integrated signals derived from antigen and IL-17A.Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.A Candida albicans Strain Expressing Mammalian Interleukin-17A Results in Early Control of Fungal Growth during Disseminated Infection.Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus.Vaccines in the treatment of invasive candidiasis.Adaptive immune responses to Candida albicans infection.Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.The C-Type Lectin Receptor MCL Mediates Vaccine-Induced Immunity against Infection with Blastomyces dermatitidis.Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.Innate immune cell response upon Candida albicans infection NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.Pathogenicity mechanisms and host response during oral Candida albicans infections.Candida antigens and immune responses: implications for a vaccine.Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species Promising immunotherapy against fungal diseases.Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines.Strategies to develop vaccines of pediatric interest.Antifungal Immunological Defenses in Newborns.Vaccine development to prevent Staphylococcus aureus surgical-site infections.Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.

P2860

Q26743448-6F32D8BA-432E-4F9F-9733-3D8BF944FA77 Q26748155-38DEC6EB-7374-4CA5-B0F7-411CC46DAC98 Q26768436-1914ADBD-C05A-4B0F-911A-91A22C62B361 Q26771113-08C81C0D-FE35-44A5-9EF7-9B93EDF38DC8 Q26776056-C6EBD9E8-F4B1-459E-9AEC-FFDFC0A6D128 Q26782272-D45198E9-FCD8-455A-9C32-AAA11B32614F Q26799351-FBFE6278-03C8-419B-B268-2D32F4814D66 Q26828993-3E1C2A75-2597-4262-8AAD-F2973557225F Q27002519-73D7602B-CB60-4B97-B99E-2CB5423B24BE Q33723258-C4CDACF7-280E-4090-8849-A8172606AC80 Q33752362-1CCEBE82-2645-4FAC-82AB-A6C78F659EC2 Q33865358-330C420C-E4DA-4A29-9169-46DF7ABDF363 Q34250054-1B1504A7-DA25-4367-BEC6-973BB76350C1 Q34304129-C66047F0-E2EA-42A4-8BAA-C3C637C4B86E Q34400249-02819BE6-F54C-4566-A2C2-480C178A8B13 Q34792962-7A739582-9BA2-4398-AA97-08A63FDE9065 Q34994764-BE20A4D4-4468-4832-A8E3-580AF3355AC5 Q35833250-188D3279-8422-4A67-A58F-D06DD87E5E40 Q35947439-90B0A2CE-0291-4908-8A7F-4EE7955CE16A Q36089061-C04174E9-AD83-45C7-B3B5-CBDBCB1ECE3D Q36138054-C90C070B-E20E-4F37-ADED-01519ED0EB2C Q36147010-0D8C29DD-88DE-44D9-B096-D7423B9F4303 Q36147114-3D6B91F5-121E-4855-B4D8-96A383E9021D Q36562397-BAA6F53B-1161-4B2B-903D-947CC7F83617 Q36631368-C1E9967A-C78A-42EE-8935-956F31372C41 Q36736262-F042D209-EC0A-4091-8C05-8BFF3B9A0591 Q37262877-A7746A63-B268-44F9-A432-BAE27BCA74CF Q37399422-473B41FF-115C-46C4-BB6E-20889B070ED0 Q38209882-AD09795C-43D2-48EF-BE63-83CF416F1C4B Q38222636-F18739D0-A9E5-4EAB-A230-5C1D0FA822A4 Q38232781-DAF00474-1E78-4373-9B59-7D263279BEF7 Q38264288-9F69A751-F618-43BD-B011-09E80380692B Q38363105-2F6FB131-7AD4-48CB-A9BA-41094CB9DE38 Q38567197-7F38EBB4-FBBD-404E-BAB4-C612F2ED690C Q38692399-E1A67E59-A435-4F44-A0F4-6BFD9969719F Q38807834-650377DF-92E7-4FA2-A74F-81A2D8B19507 Q38819027-01E7A050-078E-4D19-B06A-D06869A70054 Q38865776-2AA1EEAC-A23F-4902-B601-C48C5F7889AB Q39102571-0537BEAA-698A-4E01-B018-8BAA00CEE857 Q40183727-3BDC49BF-F70C-4CA5-920C-6788E6A23C3C

P2860

NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

http://www.wikidata.org/entity/Q30528889

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults.

@ast

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults.

@en

type

label

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults.

@ast

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults.

@en

prefLabel

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults.

@ast

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults.

@en

P1433

Q30528889-DA29BBF7-663C-4F21-B5AC-21B88AA44473

P1476

Q30528889-7D72906B-0E85-4D0B-9B0E-5B1BB39C9166

P2093

Q30528889-2CD851B7-109F-4991-B952-BBD2E81F4943

Q30528889-33F59B97-FCC5-4A4B-8FBA-3196C8600CA5

Q30528889-4A262F07-79BE-4602-A0DA-E2F159F007A2

Q30528889-77EA1541-B25F-4ACB-B01C-5A6843A50378

Q30528889-BF66090B-ED0B-46B4-A957-F5E1D615167E

Q30528889-E45690CC-9ADD-48F9-B56B-CE031D4D8303

Q30528889-EEC81DCB-701F-4DF6-82DB-530A2BC014BD

P2860

Q30528889-0AF1213F-49FB-413D-8C29-E4FAC0332D82

Q30528889-0BA40931-D22F-43A2-A50F-0C50065D277F

Q30528889-0D3AB72A-2881-4B41-871D-8239655D38E0

Q30528889-15A0C327-3853-4B53-A545-BDDE83B87576

Q30528889-164E4023-1698-4D8D-BEC0-DF5C4BC234CF

Q30528889-1E91B960-EE43-4CCE-BE61-4166E9D00795

Q30528889-23885D6F-79F3-4CA8-A7FF-323F98D76EB1

Q30528889-29AB3078-5099-4C10-88E9-2B9D63303E96

Q30528889-2AC28956-BCBE-4498-AB79-C34409A3EE0D

Q30528889-310B584E-B61E-4188-B542-954A7554F844

P304

Q30528889-5127A5FD-1F85-4870-B5F3-139D11BD1995

P31

Q30528889-11DD3BE3-2920-4BB9-AA0B-26F3DB624781

P356

Q30528889-110D6D02-BAC4-4D9C-99F3-265EA93644AE

P407

Q30528889-07AE89E3-6E11-44EE-A2B9-30B8BA027978

P433

Q30528889-4090ED96-BE53-442F-8160-56E964DA7727

P478

Q30528889-105440A0-D972-4D07-BD9E-4AD3F3367F79

P50

Q30528889-29C63CF3-4CDE-4C68-91A0-600636FD02FB

P577

Q30528889-02399579-0684-4872-9447-0B21FAAE545C

P5875

Q30528889-A7F3F389-E609-470D-8B57-41E1D814611F

P698

Q30528889-1626AA25-C50B-460E-A27F-FBF6C70CB991

P932

Q30528889-E3885131-6CDF-4C79-AD3F-64F54EF6FE7B

P356

J.VACCINE.2012.10.038

P1433

P1476

NDV-3, a recombinant alum-adju ...... immunogenic in healthy adults

@en

P2093

Ashraf S Ibrahim

http://www.w3.org/2001/XMLSchema#string

C Jo White

http://www.w3.org/2001/XMLSchema#string

Clint S Schmidt

http://www.w3.org/2001/XMLSchema#string

John E Edwards

http://www.w3.org/2001/XMLSchema#string

Michael R Yeaman

http://www.w3.org/2001/XMLSchema#string

Scott G Filler

http://www.w3.org/2001/XMLSchema#string

Yue Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Fungal invasion of normally non-phagocytic host cells

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.

Th17 cytokines and vaccine-induced immunity.

Waves of resistance: Staphylococcus aureus in the antibiotic era.

Functional and structural diversity in the Als protein family of Candida albicans.

The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

P304

7594-7600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2012.10.038

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Hennessey JP Jr

P577

2012-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232704982

http://www.w3.org/2001/XMLSchema#string

P698

23099329

http://www.w3.org/2001/XMLSchema#string

P932

3513491

http://www.w3.org/2001/XMLSchema#string